Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH2 Gene Mutation”

40 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 40 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Testing effectiveness (Phase 2)Active Not RecruitingNCT02677922
What this trial is testing

Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Who this might be right for
Leukemia, Myeloid, Acute
Celgene 130
Early research (Phase 1)UnknownNCT04806659
What this trial is testing

SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous Leukemia
Nanjing Sanhome Pharmaceutical, Co., Ltd. 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04164901
What this trial is testing

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Who this might be right for
Grade 2 GliomaResidual GliomaRecurrent Glioma
Institut de Recherches Internationales Servier 331
Testing effectiveness (Phase 2)WithdrawnNCT03881735
What this trial is testing

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Who this might be right for
Blasts Under 5 Percent of Peripheral Blood White CellsBone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment LevelIDH2 Gene Mutation+2 more
Roswell Park Cancer Institute
Not applicableUnknownNCT04369287
What this trial is testing

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIDH2 Gene Mutation
Istituto Clinico Humanitas 654
Testing effectiveness (Phase 2)Study completedNCT05282459
What this trial is testing

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Who this might be right for
LeukemiaLeukemia, MyeloidMonocytic Leukemia
Tian Yi Zhang 17
Not applicableLooking for participantsNCT07315542
What this trial is testing

Diagnostic and Therapeutic Targets in Cartilaginous Tumours

Who this might be right for
ChondrosarcomasCartilage Tumours
St. Anne's University Hospital Brno, Czech Republic 300
Early research (Phase 1)Study completedNCT02492737
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic SyndromeHematologic Malignancies
Agios Pharmaceuticals, Inc. 46
Large-scale testing (Phase 3)Study completedNCT02577406
What this trial is testing

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Who this might be right for
Leukemia, MyeloidIsocitrate Dehydrogenase
Celgene 319
Not applicableUnknownNCT02597335
What this trial is testing

Non Invasive Detection of IDH1/2 Mutation in Gliomas

Who this might be right for
GliomaIDH1/IDH2 Mutation
Assistance Publique - Hôpitaux de Paris 40
Early research (Phase 1)Active Not RecruitingNCT05441514
What this trial is testing

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center 3
Testing effectiveness (Phase 2)Ended earlyNCT03303950
What this trial is testing

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Who this might be right for
AnemiaASXL1 Gene MutationEZH2 Gene Mutation+7 more
University of Utah 6
Testing effectiveness (Phase 2)Study completedNCT04281498
What this trial is testing

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Who this might be right for
Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation
John Mascarenhas 6
Early research (Phase 1)Active Not RecruitingNCT02632708
What this trial is testing

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+2 more
Institut de Recherches Internationales Servier 153
Early research (Phase 1)Study completedNCT02071862
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Who this might be right for
Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung Cancer+7 more
Calithera Biosciences, Inc 210
Testing effectiveness (Phase 2)Active Not RecruitingNCT04203316
What this trial is testing

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Children's Oncology Group 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT03825796
What this trial is testing

CPX-351 Plus Enasidenib for Relapsed AML

Who this might be right for
Recurrent Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center 2
Load More Results